Tango Therapeutics, Inc. (TNGX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87583X1090
Tango Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 62.38 m USD |
| Operating income | -111.29 m USD |
| EBIT | -101.59 m USD |
| Net income | -101.59 m USD |
| Diluted EPS – continuing operations | -0.87 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
More stocks
- Calumet, Inc. /DE (CLMT)
- NELNET INC (NNI)
- Ansell Ltd (ANN.AX)
- Thai Oil Public Company Limited (TOP.BK)
- PIPER SANDLER COMPANIES (PIPR)
- Thai Airways International Public Company Limited (THAI.BK)
- SUZHOU TIANMAI THERMAL TECHNOLOGY (301626.SZ)
- DFI Retail Group Holdings Ltd (D01.SI)
- Wix.Com Ltd (WIX)
- AUTO1 Group (AG1.DE)
- Oji Holdings Corp (3861.T)
- Symbotic Inc. (SYM)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.